COPY OF PAPERS . . ORIGINALLY FILED



I hereby certify that this correspondence is being deposited with the United States Postal Services on the date set forth below as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231.

Date of Signature and Deposit:_

Attorney of Record

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE SEP 1 2 2002

Applicant:

Hector F. DeLuca

Serial No.:

10/074,102

TECH CENTER 1600/2900

Filed:

For:

February 12, 2002

PREPARATIONS AND USE OF AN AH

RECEPTOR LIGAND, 2-(1'H-INDOLE-3'-CARBONYL) -THIAZOLE-4-CARBOXYLİC ACID

METHYL ESTER

Group Art Unit:

1645

Examiner:

Commissioner For Patents 20231 Washington, D.C.

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. 1.98, enclosed herewith is a list of documents which the Applicants in the aboveidentified patent application wish to bring to the attention of the Examiner for consideration in connection with the examination on the merits of this patent application.

Other Documents

A. J. Philips, et al., "Synthesis of Functionalized Oxazolines and Oxazoles with DAST and Deoxo-Fluor," Organic Letter 2(8):1165-1168, 2000.

R. Susilo, et al., "Formation of Thiazolidine-4-Carboxylic Acid Represents a Main Metabolic Pathway of 5Hydroxytryptamine in Rat Brain," J. Neurochemistry 52(6):1793-1800, 1989.

The enclosed documents are part of a PCT

International Search Report that issued in a related PCT

application. Applicants state that each item of

information contained in the Information Disclosure

Statement was cited in a communication from a foreign

patent office in a counterpart foreign application not

more than three months prior to the filing of this

Information Disclosure Statement.

No fees are believed necessary to enter this Statement. However, if any fees are necessary please charge Deposit Account 17-0055.

Respectfully submitted,

Hector F. DeLuca

August 3, 2002

y: Jah

Jean C. Baker Reg. No. 35,433

Quarles & Brady LLP

411/East Wisconsin Avenue Milwaukee, WI 53202-4497

(414) 277-5709

CGPY OF PAPERS ORIGINALLY FILED

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of 2

Co	omplete if Known	
Application Number	10/074,102	
Filing Date	February 2, 2002	
First Named Inventor	Hector F. DeLuca	
Group Art Unit	1645	
Examiner Name		
Attorney Docket Number	960296.97206	

				U.S. PATENT DOCL	MENTS	
ii	Cite	U.S. Paten	t Document	Name of Patentee or Applicant	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
Examiner Initials	No.1	Number	(if known)	of Cited Document	MM-DD-YYYY	Figures Appear
						RECEIVED
						SEP 1 2 2002
						ECH CENTER 1600/2900
						EOH OF MILE 1000
	1					

				FOR	EIGN PATENT DOCUMEN	ITS		
Evaminar	Cite	F	oreign Patent Do		Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	1
Examiner Initials	No.1	Office ³	Number ⁴	(if known)	Applicant of Cited Document	MM-DD-YYYY	Figures Appear	土
								+
								_
								+
								土
		+						+
								士

		1.13
	Date	
Examiner	Considered	
Signature Signature	e with MPEP 609. Draw line through citati	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

COPY OF PAPERS

ORIGINALLY FILED

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. 10/074,102 Substitute for form 1449B/PTO **Application Number** February 2, 2002 INFORMATION DISCLOSURE Filing Date Hector F. DeLuca First Named Inventor STATEMENT BY APPLICANT 1645 **Group Art Unit Examiner Name** (use as many sheets as necessary) 960296.97206 Attorney Docket Number

Include name of the author (in CAPITAL LETTERO), tale etc.), date, page(s), volume-issue number(s), item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), date,	
Include name of the author (in CAPITAL LETTERS), titled it titled (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s). A. J. Philips, et al., "Synthesis of Functionalized Oxazolines and Oxazoles with DAST and Deoxo-Fluor," Organic Letter 2(8):1165-1168, 2000. R. Susilo, et al., "Formation of Thiazolidine-4-Carboxylic Acid Represents a Main Metabolic Pathway of 5-Hydroxytryptamine in Rat Brain," J. Neurochemistry 52/61-1703 1800 1080 RECEIVED SEP 1 2 2002	
Include name of the author (in CAPITAL LETTERS), title of title page(s), volume-issue number(s). Include name of the author (in CAPITAL LETTERS), title of title page(s), volume-issue number(s). Include name of the author (in CAPITAL LETTERS), title of title page(s), volume-issue number(s). Include name of the author (in CAPITAL LETTERS), title of title page(s), volume-issue number(s). Include name of the author (in CAPITAL LETTERS), title of title page(s), volume-issue number(s). Include name of the author (in CAPITAL LETTERS), title of title page(s), volume-issue number(s). Include name of the author (in CAPITAL LETTERS), title of title page(s), volume-issue number(s). Include name of the author (in CAPITAL LETTERS), title of title page(s), volume-issue number(s). Include name of the author (in CAPITAL LETTERS), title of title page(s), volume-issue number(s). Include name of the author (in CAPITAL LETTERS), title of title page(s), volume-issue number(s). Include name of the author (in CAPITAL LETTERS), title of title page(s), volume-issue number(s). Include name of the author (in CAPITAL LETTERS), title of title page(s), volume-issue number(s). Include name of the author (in CAPITAL ETTERS), title of title page(s), volume-issue number(s). Include name of the author (in CAPITAL ETTERS), title of title page(s), volume-issue number(s). Include name of the author (in CAPITAL ETTERS), date of the page(s), volume-issue number(s). Include name of the author (in CAPITAL ETTERS), date of the page(s), volume-issue number(s). Include name of the author (in CAPITAL ETTERS), date of the page(s), volume-issue number(s). Include name of the author (in CAPITAL ETTERS), date of the page(s), date of the page(s), volume-issue number(s). Include name of the author (in CAPITAL ETTERS), date of the page(s),	
A. J. Philips, et al., "Synthesis of Functionalized Oxazolines and Oxazoles With DAST and Deoxo-Fluor," Organic Letter 2(8):1165-1168, 2000. R. Susilo, et al., "Formation of Thiazolidine-4-Carboxylic Acid Represents a Main Metabolic Pathway of 5-Hydroxytryptamine in Rat Brain," J. Neurochemistry 52/61-1703 1800 1080 RECEIVED SEP 1 2 2002	2
R. Susilo, et al., "Formation of Thiazolidine-4-Carboxylic Acid Represents a Main Metabolic Pathway of 5-Hydroxytryptamine in Rat Brain," J. Neurochemistry 52/61-1703 1800 1080 RECEIVED SEP 1 2 2802	
SEP 1 2 2002	
TECH CENTER 1600/2500	_
	-
	-
	-
	+
	1
	_

Considered Examiner *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 5291049_1.PDF

Date

considered. Include copy of this form with next communication to applicant. ¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.